Abivax jumps as it prices $45M ADS deal to repurchase royalty certificates
ABVX•Abivax shares rose after the company priced a $45 million ADS offering tied to a deal to repurchase its 2022 royalty certificates. The stock’s move reflects investor focus on the royalty overhang removal and the offering being priced at $111.57 versus the latest trading levels.
1. What’s moving the stock today
Abivax (ABVX) is higher after announcing it executed an agreement to repurchase the royalty certificates it issued in September 2022 and, as part of that transaction, priced a $45 million offering of ADSs for the benefit of the royalty certificate holders. The ADS offering was priced at $111.57 per ADS and covers 403,347 ordinary shares represented by ADSs.
2. Why the market is reacting
Royalty-related instruments can act like a financing overhang because they divert a portion of future economics away from shareholders. The company’s move to repurchase the royalty certificates can be interpreted as simplifying the capital structure and reducing that overhang, even as the associated equity issuance introduces dilution.
3. Key numbers investors are watching
The deal size is $45 million and the offering price is $111.57 per ADS. Abivax disclosed the price was set using the volume-weighted average trading price over the five consecutive Nasdaq trading days ending May 1, 2026.
